Pulmonx Co. (NASDAQ:LUNG) Receives $14.67 Average Price Target from Brokerages

Shares of Pulmonx Co. (NASDAQ:LUNG) have been assigned an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $14.67.

Separately, Stifel Nicolaus cut their target price on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, October 31st.

Pulmonx Stock Up 2.4 %

Shares of LUNG opened at $6.45 on Friday. The firm has a market cap of $254.71 million, a P/E ratio of -4.39 and a beta of 0.68. The stock has a 50 day simple moving average of $6.87 and a two-hundred day simple moving average of $7.05. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. Pulmonx has a 1 year low of $5.46 and a 1 year high of $14.84.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. On average, analysts forecast that Pulmonx will post -1.53 earnings per share for the current fiscal year.

Insider Buying and Selling at Pulmonx

In related news, insider Geoffrey Beran Rose sold 4,586 shares of Pulmonx stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total value of $30,726.20. Following the sale, the insider now owns 295,433 shares in the company, valued at $1,979,401.10. The trade was a 1.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Glendon E. French III sold 20,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $8.09, for a total transaction of $161,800.00. Following the completion of the transaction, the director now owns 1,111,974 shares of the company’s stock, valued at $8,995,869.66. This trade represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 70,351 shares of company stock worth $494,094. 5.70% of the stock is currently owned by insiders.

Institutional Trading of Pulmonx

Several large investors have recently bought and sold shares of the company. Sei Investments Co. lifted its stake in shares of Pulmonx by 2.5% in the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock valued at $673,000 after purchasing an additional 1,800 shares during the period. Vanguard Group Inc. lifted its position in Pulmonx by 0.6% during the first quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock valued at $19,262,000 after buying an additional 11,417 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Pulmonx by 4.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 35,720 shares of the company’s stock valued at $332,000 after buying an additional 1,633 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Pulmonx by 12.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 157,902 shares of the company’s stock valued at $1,001,000 after buying an additional 17,740 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Pulmonx by 7.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after buying an additional 69,595 shares during the period. 91.04% of the stock is owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.